Resources Management Corp CT ADV lessened its stake in Kimberly-Clark Co. (NYSE:KMB – Free Report) by 20.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 4,945 shares of the company’s stock after selling 1,250 shares during the quarter. Resources Management Corp CT ADV’s holdings in Kimberly-Clark were worth $683,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in KMB. CX Institutional increased its position in shares of Kimberly-Clark by 1.2% in the 2nd quarter. CX Institutional now owns 5,968 shares of the company’s stock valued at $825,000 after purchasing an additional 71 shares during the last quarter. Capital Investment Counsel Inc increased its holdings in Kimberly-Clark by 0.8% in the first quarter. Capital Investment Counsel Inc now owns 10,019 shares of the company’s stock valued at $1,296,000 after buying an additional 75 shares during the last quarter. Connecticut Wealth Management LLC raised its stake in Kimberly-Clark by 4.6% in the first quarter. Connecticut Wealth Management LLC now owns 1,755 shares of the company’s stock valued at $227,000 after buying an additional 77 shares in the last quarter. Equitable Trust Co. lifted its holdings in Kimberly-Clark by 0.9% during the 2nd quarter. Equitable Trust Co. now owns 9,066 shares of the company’s stock worth $1,253,000 after buying an additional 80 shares during the last quarter. Finally, Comprehensive Financial Consultants Institutional Inc. boosted its position in shares of Kimberly-Clark by 1.6% during the 1st quarter. Comprehensive Financial Consultants Institutional Inc. now owns 5,093 shares of the company’s stock worth $659,000 after acquiring an additional 81 shares in the last quarter. 76.29% of the stock is currently owned by hedge funds and other institutional investors.
Kimberly-Clark Stock Performance
NYSE:KMB opened at $141.06 on Wednesday. The firm has a market cap of $47.51 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 3.00 and a beta of 0.39. The company has a debt-to-equity ratio of 5.59, a current ratio of 0.85 and a quick ratio of 0.58. Kimberly-Clark Co. has a 1-year low of $116.32 and a 1-year high of $149.30. The firm’s fifty day moving average price is $142.27 and its 200 day moving average price is $136.39.
Kimberly-Clark Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 2nd. Investors of record on Friday, September 6th will be paid a $1.22 dividend. The ex-dividend date of this dividend is Friday, September 6th. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.46%. Kimberly-Clark’s dividend payout ratio (DPR) is presently 89.71%.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. Barclays decreased their target price on Kimberly-Clark from $136.00 to $135.00 and set an “equal weight” rating for the company in a research note on Friday, July 19th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kimberly-Clark from $139.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $165.00 price target on shares of Kimberly-Clark in a research note on Wednesday, July 24th. StockNews.com downgraded shares of Kimberly-Clark from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 30th. Finally, Piper Sandler lifted their target price on Kimberly-Clark from $167.00 to $174.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $145.67.
Check Out Our Latest Research Report on Kimberly-Clark
Insider Buying and Selling
In other Kimberly-Clark news, insider Gonzalo Uribe sold 1,780 shares of the firm’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $140.84, for a total value of $250,695.20. Following the completion of the sale, the insider now owns 7,377 shares of the company’s stock, valued at $1,038,976.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, insider Gonzalo Uribe sold 1,780 shares of Kimberly-Clark stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $140.84, for a total transaction of $250,695.20. Following the completion of the sale, the insider now directly owns 7,377 shares in the company, valued at approximately $1,038,976.68. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey P. Melucci sold 37,699 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $141.42, for a total value of $5,331,392.58. Following the sale, the insider now owns 19,935 shares in the company, valued at $2,819,207.70. The disclosure for this sale can be found here. 0.62% of the stock is currently owned by corporate insiders.
Kimberly-Clark Company Profile
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company’s Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names.
Recommended Stories
- Five stocks we like better than Kimberly-Clark
- Top Stocks Investing in 5G Technology
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Want to see what other hedge funds are holding KMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kimberly-Clark Co. (NYSE:KMB – Free Report).
Receive News & Ratings for Kimberly-Clark Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kimberly-Clark and related companies with MarketBeat.com's FREE daily email newsletter.